Forschung

Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sektionen
AG Hamprecht
Sie sind hier: Startseite / Forschung / AG Hamprecht

AG Hamprecht

foto-ag-hamprecht.jpg

Group Leader: Priv.-Doz. Dr. med. Axel Hamprecht
Phone: +49 221 478 32162
E-Mail: [Email protection active, please enable JavaScript.]

Co-workers:
Ahmad Saleh
Yvonne Stelzer
Dr. rer. nat. Thorsten Wille

MD students
Katharina Füßl
Hanna Gistl
Florian Koroska
Maria Meier
Esther Parting
Tsvetan Tsvetkov


Research Topic:

Resistance mechanisms in gram-negative bacteria

Detection and resistance of medically important fungi

Resistance mechanisms in gram-negative bacteria
Resistance to antibiotics has dramatically increased in recent years, especially among gram-negative bacteria (e.g., Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa). These bacteria cause life threatening infections (e.g. sepsis, pneumonia) and can be transmitted from patient to patient.

In the last years, we witness an increasing resistance to commonly used beta-lactam antibiotics, especially to extended spectrum cephalosporins. Resistance is commonly caused by extended spectrum beta lactamases that can hydrolyze many beta lactams.

Another threat which is still rare in Germany is the resistance to carbapenems (e.g., ertapenem, meropenem, imipenem), which is caused by carbapenemases such as NDM (New Delhi metallo-beta-lactamase), KPC, VIM, OXA-48 and others.

The main interest of our group is to identify and characterize resistant Gram-negative bacteria and to understand why some species and clones can disseminate successfully.

Furthermore, we work on the rapid detection of carbapenemase-producing Enterobacteriaceae directly from clinical specimen.

azole-resistant-aspergillus-fumigatus.jpg

Azole-resistant Aspergillus fumigatus (TR46/Y121F/T289A mutation)

Detection and resistance of medically important fungi
With the growing number of immune-compromised patients, we see an increasing number of infections by opportunistic pathogens, especially fungi. Invasive fungal infections such as aspergillosis show a very high mortality and are particularly difficult to treat. This problem has been aggravated by an increasing resistance to triazole antifungals, the mainstay of aspergillosis therapy. This phenomenon has only been observed in the last years and is likely caused the use of azole fungicides in agriculture.

Our current research focuses on azole resistance in Aspergillus spp. and the detection and resistance of “rare” fungi, such as Fusarium spp.


Brief description in German
Unsere Arbeitsgruppe beschäftigt sich mit Resistenzen und Resistenzmechanismen von gram-negativen Bakterien und medizinisch wichtigen Pilzen.

Resistenzen gegenüber Antibiotika und Antimykotika haben in den letzten Jahren dramatisch zugenommen. Dies ist u.a. bedingt durch den zu häufigen Einsatz von Antibiotika (Klinik, ambulant, Tierhaltung) und von Antimykotika (Landwirtschaft).

Unsere Arbeitsgruppe hat sich zum Ziel gesetzt, resistente Stämme nachzuweisen und zu charakterisieren sowie die zugrundeliegenden Resistenzmechanismen aufzuklären. Unser Hauptinteresse liegt hierbei bei Antibiotikaresistenzen gegenüber Betalaktamen (z.B. durch ESBLs oder Carbapenemasen wie NDM, KPC, OXA-48 u.a.) und Antimykotikaresistenzen bei Aspergillus spp. gegenüber Triazolen.

 

Selected publications

Jazmati, N., Jazmati T, Hamprecht A. Importance of pre-enrichment for detection of third-generation cephalosporin-resistant Enterobacteriaceae (3GCREB) from rectal swabs. Eur J Clin Microbiol Infect Dis 2017, May 5 [Epub ahead of print]

Walther G, Stasch S, Kaerger K, Hamprecht A, Roth M, Cornely OA, Geerling G, Mackenzie CR, Kurzai O, von Lilienfeld-Toal M. Fusarium Keratitis in Germany. J Clin Microbiol. 2017 [Epub ahead of print]

Alanio A, Gits-Muselli M, Guigue N, Desnos-Ollivier M, Calderon EJ, Di Cave D, Dupont D, Hamprecht A, Hauser PM, Helweg-Larsen J, Kicia M, Lagrou K, Lengerova M, Matos O, Melchers WJG, Morio F, Nevez G, Totet A, White LP, Bretagne S. Diversity of Pneumocystis jirovecii Across Europe: A Multicentre Observational Study. EBioMedicine. 2017 Aug;22:155-163. doi: 10.1016/j.ebiom.2017.06.027

Hamprecht A, Morio F, Bader O, Le Pape P, Steinmann J, Dannaoui E. Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern? Mycopathologia. 2017 Jun 26. doi: 10.1007/s11046-017-0162-4.

Weber M, Schaer J, Walther G, Kaerger K, Steinmann J, Rath PM, Spiess B, Buchheidt D, Hamprecht A, Kurzai O. FunResDB-A web resource for genotypic susceptibility testing of Aspergillus fumigatus. Med Mycol. 2017 Mar 11. doi: 10.1093/mmy/myx015.

Koroska F, Göttig S, Kaase M, Steinmann J, Gatermann S, Sommer J, Wille T, Plum G, Hamprecht A. Comparison of Phenotypic Tests and an Immunochromatographic  Assay and Development of a New Algorithm for Detection of OXA-48-like Carbapenemases.
J Clin Microbiol. 2017 Mar;55(3):877-883. doi: 10.1128/JCM.01929-16.

Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekulé A, Keller P, Kiehl M, Krause SW, Krämer C, Neumann S, Rohde H, La Rosée P, Ruhnke M, Schafhausen P, Schalk E, Schulz K, Schwartz S, Silling G, Staib P, Ullmann A, Vergoulidou M, Weber T, Cornely OA, Vehreschild MJ. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. Int J Antimicrob Agents. 2017 Feb;49(2):218-223. doi: 10.1016/j.ijantimicag.2016.10.019.

Gruber TM, Göttig S, Mark L, Christ S, Kempf VA, Wichelhaus TA and Hamprecht A
Pathogenicity of pan-drug-resistant Serratia marcescens harbouring blaNDM-1. J Antimicrob Chemother. 2014 Dec 2

Hamprecht A and Göttig S. Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. Curr Treat Options Infect Dis Aug 2014, DOI 10.1007/s40506-014-0029-x

Steinmann J, Hamprecht A, Vehreschild MJ, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015 May;70(5):1522-6. doi: 10.1093/jac/dku566.

Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. 2014 Dec;69(12):3387-92. doi: 10.1093/jac/dku305

Spiess B, Postina P, Reinwald M, Cornely OA, Hamprecht A, Hoenigl M, Lass-Flörl C, Rath PM, Steinmann J, Miethke T, Lauten M, Will S, Merker N, Hofmann WK, Buchheidt D. Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013. PLoS One. 2014 Jul 29;9(7):e103113. doi: 10.1371/journal.pone.0103113.

Maschmeyer G, Carratalà J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E; Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2015 Jan;26(1):21-33. doi: 10.1093/annonc/mdu192.

Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, Vehreschild MJ, Wisplinghoff H, Krönke M, Hamprecht A. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother. 2014 Jun;69(6):1533-6. doi: 10.1093/jac/dku009.

Hamprecht A, Christ S, Oestreicher T, Plum G, Kempf VA, Göttig S. Performance of two MALDI-TOF MS systems for the identification of yeasts isolated from bloodstream infections and cerebrospinal fluids using a time-saving direct transfer protocol. Med Microbiol Immunol. 2014 Apr;203(2):93-9. doi: 10.1007/s00430-013-0319-9.

Göttig S, Hamprecht AG, Christ S, Kempf VA, Wichelhaus TA. Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-β-lactamase with increased carbapenemase activity. J Antimicrob Chemother. 2013 Aug;68(8):1737-40. doi: 10.1093/jac/dkt088

Hamprecht A, Poirel L, Göttig S, Seifert H, Kaase M, Nordmann P. Detection of the carbapenemase GIM-1 in Enterobacter cloacae in Germany. J Antimicrob Chemother. 2013 Mar;68(3):558-61. doi: 10.1093/jac/dks447

Hamprecht A, Buchheidt D, Vehreschild JJ, Cornely OA, Spiess B, Plum G, Halbsguth TV, Kutsch N, Stippel D, Kahl P, Persigehl T, Steinbach A, Bos B, Hallek M, Vehreschild MJ. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill. 2012 Sep 6;17(36):20262.

 

Offene Stellen
Offene Stellen sind unter der Rubrik „Stellen“ auf der Homepage des IMMIH aufgeführt.
Für Projekte im Rahmen von Master- oder Diplomarbeiten suchen wir immer engagierte und hoch motivierte Studenten. Für diese und andere Anfragen wenden Sie sich bitte direkt an den Gruppenleiter.